ARCHIVES

AACR thanks NCI for funds, provides platform for von Eschenbach’s 2015 goal. Also 2015 goal not a dream, but a vision, NCI director says.

This article is from The Cancer Letter archive.

Vol. 29 No. | August 12, 2003

Download PDF Visit The Full Archive

Related Articles

Tasigna Shows High Response, PFS Benefit Compared to Gleevec in Phase III CML Study

December 26, 2014

Editorial: Ambiance Through Exclusion

May 20, 1994

SEER Program Expansion Through Cost-Sharing.

March 23, 2001

New Safety Concerns On ESAs Prompt FDA To Consult ODAC Again.

January 11, 2008

Phase III Xilonix Study Halted Following Unscheduled Analysis

September 26, 2014

Children With Recurrent Hodgkin’s Respond To Gemcitabine, Vinorelbine

March 27, 2009